Reports

Global Cell Therapy Market to Grow at a CAGR of 18.1% During 2024-2032, Aided by Increasing Investment in Healthcare Sector

Sale

Global Cell Therapy Market Size, Trends, Growth, Forecast: By Type: Stem Cell, Non-Stem Cell (Dendritic Cell, CART-Cell); By Type of Therapy: Autologous, Allogeneic; By Therapeutic Area: Musculoskeletal Disorders, Cardiovascular Diseases, Neurological Disorders, Others; By End User; Regional Anlysis; Supplier Landscape; 2024-2032

Competitive Landscape

The key features of the global cell therapy market report include patent analysis, clinical trial analysis, grant analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:

Vericel Corporation

Vericel Corporation is a public, American biopharmaceutical company, with a manufacturing facility in Massachusetts (Cambridge). It develops and markets advanced cell therapies in areas of sports medicine and severe burn care and has a robust presence in the U.S. cell therapy market. The company has a strong product portfolio including autologous cultured chondrocytes on porcine collagen membrane (MACI) to treat cartilage defects and Epicel cultured epidermal autografts for skin replacement. The biopharma company also holds an exclusive license for NexoBrid (anacaulase-bcdb) in North America for treating severe thermal burns.

Kolon TissueGene Inc.

This biotechnology company specializes in the development of cell and gene therapies for the treatment of osteoarthritis and other orthopedic conditions. Its novel cell and gene therapy for knee osteoarthritis, INVOSSA-K, was approved in South Korea in 2017 but was later retracted in 2019. Kolon TissueGene is actively working on the preclinical and clinical development of its pipeline products to expand its cell and gene therapies portfolio for treating various orthopedic and musculoskeletal disorders and is expected to significantly contribute to bringing cell therapy innovations into the market.

JCR Pharmaceuticals Co. Ltd

This Japanese biopharmaceutical company focuses on the development and commercialization of innovative therapies, including cell and gene therapies. Its allogeneic cell therapy JR-031 (Temcell HS Inj.) is a mesenchymal stem cell (MSC) therapy used to treat graft-versus-host disease (GVHD). The company heavily invests in R&D activities and has several cell therapy candidates in various stages of preclinical and clinical development. The pharmaceutical company is also aiming for global commercialization via strategic partnerships with international companies and is likely to elevate the cell therapy market value in the forecast period.

MEDIPOST Co. Ltd.

MEDIPOST Co. Ltd., a South Korean biotechnology company, has a prominent presence in the market. Its allogeneic umbilical cord blood-derived mesenchymal stem cell therapy, Cartistem, is designed for the treatment of knee cartilage defects and osteoarthritis. The company is known to actively collaborate with academic institutions, research organizations, and other biotech companies to advance and expand its cell therapy pipeline.

Other players in the cell therapy market include Osiris (Mesoblast), Stemedica Cell Technologies Inc., ImmunoACT, Castle Creek Biosciences, Inc., PHARMICELL Co. Ltd, ANTEROGEN.CO.LTD, Novartis AG, Celgene Corp. (Bristol-Myers Squibb Company), Allogene Therapeutics Inc., and Stempeutics Research Pvt. Ltd, among others.

Cell Therapy Market Report Snapshots

Cell Therapy Market Size

Cell Therapy Market Trends

Cell Therapy Market Share

Cell Therapy Companies

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.

1   Preface
   1.1   Objectives of the Study
   1.2   Key Assumptions
   1.3   Report Coverage – Key Segmentation and Scope
   1.4   Research Methodology
2   Executive Summary
3   Global Cell Therapy Market Overview
   3.1   Global Cell Therapy Market Historical Value (2017-2023)
   3.2   Global Cell Therapy Market Forecast Value (2024-2032)
4   Vendor Positioning Analysis
   4.1   Key Vendors
   4.2   Prospective Leaders
   4.3   Niche Leaders
   4.4   Disruptors
5   Global Cell Therapy Market Landscape*
   5.1   Global Cell Therapy: Developers Landscape
       5.1.1   Analysis by Year of Establishment
       5.1.2   Analysis by Company Size
       5.1.3   Analysis by Region
   5.2   Global Cell Therapy: Product Landscape
       5.2.1   Analysis by Type
       5.2.2   Analysis by Type of Therapy
       5.2.3   Analysis by End User
6   Global Cell Therapy Market Dynamics
   6.1   Market Drivers and Constraints
   6.2   SWOT Analysis
       6.2.1   Strengths
       6.2.2   Weaknesses
       6.2.3   Opportunities
       6.2.4   Threats
   6.3   PESTEL Analysis
       6.3.1   Political
       6.3.2   Economic
       6.3.3   Social
       6.3.4   Technological
       6.3.5   Legal
       6.3.6   Environment
   6.4   Porter’s Five Forces Model
       6.4.1   Bargaining Power of Suppliers
       6.4.2   Bargaining Power of Buyers
       6.4.3   Threat of New Entrants
       6.4.4   Threat of Substitutes
       6.4.5   Degree of Rivalry
   6.5   Key Demand Indicators
   6.6   Key Price Indicators
   6.7   Industry Events, Initiatives, and Trends
   6.8   Value Chain Analysis
7   Global Cell Therapy Market Segmentation (2017-2032)
   7.1   Global Cell Therapy Market (2017-2032) by Type
       7.1.1   Market Overview
       7.1.2   Stem Cell
           7.1.2.1   Bone Marrow Derived Mesenchymal Stem Cell
           7.1.2.2   Hematopoietic Stem Cells
           7.1.2.3   Umbilical Cord Derived Stem Cell
           7.1.2.4   Adipose Derived Stem Cell
           7.1.2.5   Skin Stem Cells
           7.1.2.6   Induced Pluripotent Stem Cells
           7.1.2.7   Others
       7.1.3   Non-Stem Cell (Dendritic Cell, CART-Cell)
   7.2   Global Cell Therapy Market (2017-2032) by Type of Therapy
       7.2.1   Market Overview
       7.2.2   Autologous
       7.2.3   Allogeneic
   7.3   Global Cell Therapy Market (2017-2032) by Therapeutic Area
       7.3.1   Market Overview
       7.3.2   Musculoskeletal Disorders
       7.3.3   Cardiovascular Diseases
       7.3.4   Neurological Disorders
       7.3.5   Oncological Disorders
       7.3.6   Dermatology
       7.3.7   Inflammatory And Autoimmune Disorders
       7.3.8   Others
   7.4   Global Cell Therapy Market (2017-2032) by End User
       7.4.1   Market Overview
       7.4.2   Hospitals and Clinics
       7.4.3   Regenerative Medicine Centers
       7.4.4   Diagnostic and Research Centers
       7.4.5   Others
   7.5   Global Cell Therapy Market (2017-2032) by Region
       7.5.1   Market Overview
       7.5.2   North America
       7.5.3   Europe
       7.5.4   Asia Pacific
       7.5.5   Latin America
       7.5.6   Middle East and Africa
8   North America Cell Therapy Market (2017-2032)
   8.1   North America Cell Therapy Market (2017-2032) by Type
       8.1.1   Market Overview
       8.1.2   Stem Cell
           8.1.2.1   Bone Marrow Derived Mesenchymal Stem Cell
           8.1.2.2   Hematopoietic Stem Cells
           8.1.2.3   Umbilical Cord Derived Stem Cell
           8.1.2.4   Adipose Derived Stem Cell
           8.1.2.5   Skin Stem Cells
           8.1.2.6   Induced Pluripotent Stem Cells
           8.1.2.7   Others
       8.1.3   Non-Stem Cell (Dendritic Cell, CART-Cell)
   8.2   North America Cell Therapy Market (2017-2032) by Type of Therapy
       8.2.1   Market Overview
       8.2.2   Autologous
       8.2.3   Allogeneic
   8.3   North America Cell Therapy Market (2017-2032) by Therapeutic Area
       8.3.1   Market Overview
       8.3.2   Musculoskeletal Disorders
       8.3.3   Cardiovascular Diseases
       8.3.4   Neurological Disorders
       8.3.5   Oncological Disorders
       8.3.6   Dermatology
       8.3.7   Inflammatory And Autoimmune Disorders
       8.3.8   Others
   8.4   North America Cell Therapy Market (2017-2032) by End User
       8.4.1   Market Overview
       8.4.2   Hospitals and Clinics
       8.4.3   Regenerative Medicine Centers
       8.4.4   Diagnostic and Research Centers
       8.4.5   Others
   8.5   North America Cell Therapy Market (2017-2032) by Country
       8.5.1   United States of America
       8.5.2   Canada
9   Europe Cell Therapy Market (2017-2032)
   9.1   Europe Cell Therapy Market (2017-2032) by Type
       9.1.1   Market Overview
       9.1.2   Stem Cell
           9.1.2.1   Bone Marrow Derived Mesenchymal Stem Cell
           9.1.2.2   Hematopoietic Stem Cells
           9.1.2.3   Umbilical Cord Derived Stem Cell
           9.1.2.4   Adipose Derived Stem Cell
           9.1.2.5   Skin Stem Cells
           9.1.2.6   Induced Pluripotent Stem Cells
           9.1.2.7   Others
       9.1.3   Non-Stem Cell (Dendritic Cell, CART-Cell)
   9.2   Europe Cell Therapy Market (2017-2032) by Type of Therapy
       9.2.1   Market Overview
       9.2.2   Autologous
       9.2.3   Allogeneic
   9.3   Europe Cell Therapy Market (2017-2032) by Therapeutic Area
       9.3.1   Market Overview
       9.3.2   Musculoskeletal Disorders
       9.3.3   Cardiovascular Diseases
       9.3.4   Neurological Disorders
       9.3.5   Oncological Disorders
       9.3.6   Dermatology
       9.3.7   Inflammatory And Autoimmune Disorders
       9.3.8   Others
   9.4   Europe Cell Therapy Market (2017-2032) by End User
       9.4.1   Market Overview
       9.4.2   Hospitals and Clinics
       9.4.3   Regenerative Medicine Centers
       9.4.4   Diagnostic and Research Centers
       9.4.5   Others
   9.5   Europe Cell Therapy Market (2017-2032) by Country
       9.5.1   United Kingdom
       9.5.2   Germany
       9.5.3   France
       9.5.4   Italy
       9.5.5   Others
10   Asia Pacific Cell Therapy Market (2017-2032)
   10.1   Asia Pacific Cell Therapy Market (2017-2032) by Type
       10.1.1   Market Overview
       10.1.2   Stem Cell
           10.1.2.1   Bone Marrow Derived Mesenchymal Stem Cell
           10.1.2.2   Hematopoietic Stem Cells
           10.1.2.3   Umbilical Cord Derived Stem Cell
           10.1.2.4   Adipose Derived Stem Cell
           10.1.2.5   Skin Stem Cells
           10.1.2.6   Induced Pluripotent Stem Cells
           10.1.2.7   Others
       10.1.3   Non-Stem Cell (Dendritic Cell, CART-Cell)
   10.2   Asia Pacific Cell Therapy Market (2017-2032) by Type of Therapy
       10.2.1   Market Overview
       10.2.2   Autologous
       10.2.3   Allogeneic
   10.3   Asia Pacific Cell Therapy Market (2017-2032) by Therapeutic Area
       10.3.1   Market Overview
       10.3.2   Musculoskeletal Disorders
       10.3.3   Cardiovascular Diseases
       10.3.4   Neurological Disorders
       10.3.5   Oncological Disorders
       10.3.6   Dermatology
       10.3.7   Inflammatory And Autoimmune Disorders
       10.3.8   Others
   10.4   Asia Pacific Cell Therapy Market (2017-2032) by End User
       10.4.1   Market Overview
       10.4.2   Hospitals and Clinics
       10.4.3   Regenerative Medicine Centers
       10.4.4   Diagnostic and Research Centers
       10.4.5   Others
   10.5   Asia Pacific Cell Therapy Market (2017-2032) by Country
       10.5.1   China
       10.5.2   Japan
       10.5.3   India
       10.5.4   ASEAN
       10.5.5   Australia
       10.5.6   Others
11   Latin America Cell Therapy Market (2017-2032)
   11.1   Latin America Cell Therapy Market (2017-2032) by Type
       11.1.1   Market Overview
       11.1.2   Stem Cell
           11.1.2.1   Bone Marrow Derived Mesenchymal Stem Cell
           11.1.2.2   Hematopoietic Stem Cells
           11.1.2.3   Umbilical Cord Derived Stem Cell
           11.1.2.4   Adipose Derived Stem Cell
           11.1.2.5   Skin Stem Cells
           11.1.2.6   Induced Pluripotent Stem Cells
           11.1.2.7   Others
       11.1.3   Non-Stem Cell (Dendritic Cell, CART-Cell)
   11.2   Latin America Cell Therapy Market (2017-2032) by Type of Therapy
       11.2.1   Market Overview
       11.2.2   Autologous
       11.2.3   Allogeneic
   11.3   Latin America Cell Therapy Market (2017-2032) by Therapeutic Area
       11.3.1   Market Overview
       11.3.2   Musculoskeletal Disorders
       11.3.3   Cardiovascular Diseases
       11.3.4   Neurological Disorders
       11.3.5   Oncological Disorders
       11.3.6   Dermatology
       11.3.7   Inflammatory And Autoimmune Disorders
       11.3.8   Others
   11.4   Latin America Cell Therapy Market (2017-2032) by End User
       11.4.1   Market Overview
       11.4.2   Hospitals and Clinics
       11.4.3   Regenerative Medicine Centers
       11.4.4   Diagnostic and Research Centers
       11.4.5   Others
   11.5   Latin America Cell Therapy Market (2017-2032) by Country
       11.5.1   Brazil
       11.5.2   Argentina
       11.5.3   Mexico
       11.5.4   Others
12   Middle East and Africa Cell Therapy Market (2017-2032)
   12.1   Middle East and Africa Cell Therapy Market (2017-2032) by Type
       12.1.1   Market Overview
       12.1.2   Stem Cell
           12.1.2.1   Bone Marrow Derived Mesenchymal Stem Cell
           12.1.2.2   Hematopoietic Stem Cells
           12.1.2.3   Umbilical Cord Derived Stem Cell
           12.1.2.4   Adipose Derived Stem Cell
           12.1.2.5   Skin Stem Cells
           12.1.2.6   Induced Pluripotent Stem Cells
           12.1.2.7   Others
       12.1.3   Non-Stem Cell (Dendritic Cell, CART-Cell)
   12.2   Middle East and Africa Cell Therapy Market (2017-2032) by Type of Therapy
       12.2.1   Market Overview
       12.2.2   Autologous
       12.2.3   Allogeneic
   12.3   Middle East and Africa Cell Therapy Market (2017-2032) by Therapeutic Area
       12.3.1   Market Overview
       12.3.2   Musculoskeletal Disorders
       12.3.3   Cardiovascular Diseases
       12.3.4   Neurological Disorders
       12.3.5   Oncological Disorders
       12.3.6   Dermatology
       12.3.7   Inflammatory And Autoimmune Disorders
       12.3.8   Others
   12.4   Middle East and Africa Cell Therapy Market (2017-2032) by End User
       12.4.1   Market Overview
       12.4.2   Hospitals and Clinics
       12.4.3   Regenerative Medicine Centers
       12.4.4   Diagnostic and Research Centers
       12.4.5   Others
   12.5   Middle East and Africa Cell Therapy Market (2017-2032) by Country
       12.5.1   Saudi Arabia
       12.5.2   United Arab Emirates
       12.5.3   Nigeria
       12.5.4   South Africa
       12.5.5   Others
13   Regulatory Framework
   13.1   Regulatory Overview
   13.2   US FDA
   13.3   EU EMA
   13.4   INDIA CDSCO
   13.5   JAPAN PMDA
   13.6   Others
14   Patent Analysis
   14.1   Analysis by Type of Patent
   14.2   Analysis by Publication Year
   14.3   Analysis by Issuing Authority
   14.4   Analysis by Patent Age
   14.5   Analysis by CPC Analysis
   14.6   Analysis by Patent Valuation
   14.7   Analysis by Key Players
15   Clinical Trial Analysis
   15.1   Analysis by Trial Registration Year
   15.2   Analysis by Trial Status
   15.3   Analysis by Trial Phase
   15.4   Analysis by Therapeutic Area
   15.5   Analysis by Geography
16   Grant Analysis
   16.1   Analysis by Year
   16.2   Analysis by Amount Awarded
   16.3   Analysis by Issuing Authority
   16.4   Analysis by Grant Product
   16.5   Analysis by Funding Institute
   16.6   Analysis by Departments
   16.7   Analysis by Recipient Organization
17   Funding and Investment Analysis
   17.1   Analysis by Funding Instances
   17.2   Analysis by Type of Funding
   17.3   Analysis by Funding Amount
   17.4   Analysis by Leading Players
   17.5   Analysis by Leading Investors
   17.6   Analysis by Geography
18   Strategic Initiatives
   18.1   Analysis by Partnership Instances
   18.2   Analysis by Type of Partnership
   18.3   Analysis by Leading Players
   18.4   Analysis by Geography
19   Supplier Landscape
   19.1   Market Share Analysis, By Region (Top 5 Companies)
       19.1.1   Market Share Analysis: Global
       19.1.2   Market Share Analysis: North America
       19.1.3   Market Share Analysis: Europe
       19.1.4   Market Share Analysis: Asia-Pacific
       19.1.5   Market Share Analysis: Others
   19.2   Vericel Corporation
       19.2.1   Financial Analysis
       19.2.2   Product Portfolio
       19.2.3   Demographic Reach and Achievements
       19.2.4   Mergers and Acquisitions
       19.2.5   Certifications
   19.3   Kolon TissueGene Inc .
       19.3.1   Financial Analysis
       19.3.2   Product Portfolio
       19.3.3   Demographic Reach and Achievements
       19.3.4   Mergers and Acquisitions
       19.3.5   Certifications
   19.4   JCR Pharmaceuticals Co. Ltd
       19.4.1   Financial Analysis
       19.4.2   Product Portfolio
       19.4.3   Demographic Reach and Achievements
       19.4.4   Mergers and Acquisitions
       19.4.5   Certifications
   19.5   MEDIPOST Co. Ltd .
       19.5.1   Financial Analysis
       19.5.2   Product Portfolio
       19.5.3   Demographic Reach and Achievements
       19.5.4   Mergers and Acquisitions
       19.5.5   Certifications
   19.6   Osiris (Mesoblast)
       19.6.1   Financial Analysis
       19.6.2   Product Portfolio
       19.6.3   Demographic Reach and Achievements
       19.6.4   Mergers and Acquisitions
       19.6.5   Certifications
   19.7   Stemedica Cell Technologies Inc .
       19.7.1   Financial Analysis
       19.7.2   Product Portfolio
       19.7.3   Demographic Reach and Achievements
       19.7.4   Mergers and Acquisitions
       19.7.5   Certifications
   19.8   ImmunoACT
       19.8.1   Financial Analysis
       19.8.2   Product Portfolio
       19.8.3   Demographic Reach and Achievements
       19.8.4   Mergers and Acquisitions
       19.8.5   Certifications
   19.9   Castle Creek Biosciences, Inc .
       19.9.1   Financial Analysis
       19.9.2   Product Portfolio
       19.9.3   Demographic Reach and Achievements
       19.9.4   Mergers and Acquisitions
       19.9.5   Certifications
   19.10   PHARMICELL Co. Ltd
       19.10.1   Financial Analysis
       19.10.2   Product Portfolio
       19.10.3   Demographic Reach and Achievements
       19.10.4   Mergers and Acquisitions
       19.10.5   Certifications
   19.11   ANTEROGEN.CO.LTD
       19.11.1   Financial Analysis
       19.11.2   Product Portfolio
       19.11.3   Demographic Reach and Achievements
       19.11.4   Mergers and Acquisitions
       19.11.5   Certifications
   19.12   Novartis AG
       19.12.1   Financial Analysis
       19.12.2   Product Portfolio
       19.12.3   Demographic Reach and Achievements
       19.12.4   Mergers and Acquisitions
       19.12.5   Certifications
   19.13   Celgene Corp. (Bristol-Myers Squibb Company)
       19.13.1   Financial Analysis
       19.13.2   Product Portfolio
       19.13.3   Demographic Reach and Achievements
       19.13.4   Mergers and Acquisitions
       19.13.5   Certifications
   19.14   Allogene Therapeutics Inc .
       19.14.1   Financial Analysis
       19.14.2   Product Portfolio
       19.14.3   Demographic Reach and Achievements
       19.14.4   Mergers and Acquisitions
       19.14.5   Certifications
   19.15   Stempeutics Research Pvt. Ltd
       19.15.1   Financial Analysis
       19.15.2   Product Portfolio
       19.15.3   Demographic Reach and Achievements
       19.15.4   Mergers and Acquisitions
       19.15.5   Certifications
20   Global Cell Therapy Market – Distribution Model (Additional Insight)
   20.1   Overview
   20.2   Potential Distributors
   20.3   Key Parameters for Distribution Partner Assessment
21   Key Opinion Leaders (KOL) Insights (Additional Insight)
22   Payment Methods (Additional Insight)
   22.1   Government Funded
   22.2   Private Insurance
   22.3   Out-of-Pocket

*Additional insights provided are customisable as per client requirements.

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

**The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.

Request Sample

Purchase Full Report

Datasheet

$ ~~2969~~ $2699

Selected Sections, One User
Printing Not Allowed
Email Delivery in PDF
~~Free Limited Customisation~~
~~Post Sales Analyst Support~~
~~50% Discount on Next Update~~

Buy Now

Single User License

$ ~~5499~~ $4999

All Sections, One User
One Print Allowed
Email Delivery in PDF
~~Free Limited Customisation~~
~~Post Sales Analyst Support~~
~~50% Discount on Next Update~~

Buy Now

Five User License

$ ~~6599~~ $5999

All Sections, Five Users
Five Prints Allowed
Email Delivery in PDF
Free Limited Customisation
Post Sales Analyst Support
~~50% Discount on Next Update~~

Buy Now

Corporate License

$ ~~7699~~ $6999

All Sections, Unlimited Users
Unlimited Prints Allowed
Email Delivery in PDF + Excel
Free Limited Customisation
Post Sales Analyst Support
50% Discount on Next Update

Buy Now

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation

Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER